Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A

Abstract

What is claimed is: 1. A pharmaceutical composition comprising: (i) an expression construct comprising a first promoter functional in eukaryotic cells and a first nucleic acid encoding a p53-specific ribozyme, wherein said first nucleic acid is under transcriptional control of said first promoter;